Monday, 22 Jan 2018

You are here

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.

Nearly 30 million adults in the United States have OAS. Moreover the majority of OSA remains undiagnosed.  It is  characterized by recurrent complete (apnea) or partial (hypopnea) obstruction of the upper airway during sleep, resulting in snoring, intermittent hypoxemia and hypercapnia, and sleep fragmentation.

Major recommendations

  • Screening questionnaires and prediction algorithms should not be used to diagnose OSA in the absence of polysomnography or home sleep apnea testing (HSAT) (moderate evidence; strong recommendation).
  • Facility-based polysomnography or HSAT with a technically adequate device should be used for diagnosis of OSA in uncomplicated adult cases with suspected moderate to severe OSA (moderate evidence; strong recommendation).
  • Facility-based polysomnography, rather than HSAT, should be used for diagnosis of OSA in complicated cases (those with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspected sleep-related hypoventilation, chronic opioid medication use, history of stroke, or severe insomnia) (very weak evidence; strong recommendation).
  • When facility-based polysomnography is used, a split-night (rather than full-night) diagnostic protocol should be used for diagnosis of OSA (low evidence; weak recommendation).

The US Preventive Services Task Force has stated that there is insufficient evidence to support routine screening for OSA in asymptomatic adults.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cannibis Weakly Effective in Neuropathic Pain

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

However, there was little evidence that cannabis can alleviate pain associated with multiple sclerosis, cancer, or rheumatic conditions.  

Fibromyalgia Diagnosed by Two Simple Tests

Researchers from the Oregon Health Science Center have reported that fibromyalgia can be distinguished from chronic pain by primary care providers (PCPs) who employ two simple screening tests: BP cuff-evoked pain and a single patient question, and pain induced by pinching the Achilles tendon. 

Opioid Crisis Costs US $500 Billion

Reuters reports that the opioid crisis has cost the United States as much as $504 billion in 2015,  based on a White House economists report released this week. The White House Council of Economic Advisers (CEA) said the toll from the opioid crisis represented 2.8% of gross domestic product that year.

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.

High Drug Discontinuations and Nonadherence in Fibromyalgia

Compliance and adherence was shown to be quite poor in fibromyalgia (FM) patients, with high rates of drug discontinuation and greater than 60% demonstrated low adherence.